Cronos Group Inc.
NASDAQ:CRONDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $1.16B
- Beta
- 1.25
- P/E (TTM)
- -488.3
- EPS (TTM)
- -$0.01
Volume 1.13M
Average 1.51M
CRON Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Cronos Group Inc.NASDAQ: CRON
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q1 FY2026 net change in cash was $34.21M, compared with -$60.99M a year earlier. Trailing-twelve-month net change in cash was $27.5M. Over 3 fiscal years it compounded at -17.8% a year.
Context
- Net change in cash amounted to 45.6% of revenue in FY2025, down 115.6 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near $34.21M or moves back toward the trailing-twelve-month quarterly average of $6.88M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (67.94M) USD
- Year-over-year change
- -135.9%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (67.94M) | -135.9% |
| FY2024 | 2024-12-31 | 189.51M | +298.7% |
| FY2023 | 2023-12-31 | (95.35M) | +22.1% |
| FY2022 | 2022-12-31 | (122.33M) | +36.0% |
| FY2021 | 2021-12-31 | (191.05M) | — |
Net Change in Cash vs competitors
How CRON compares with its peers on the latest reported figures
- CRON's LTM Mar 2026 net change in cash of $27.5M is the 6th largest of the 11 companies compared; the peer median is $3.08M.
- Its year-over-year change of +148.0% is the 5th highest of 11, against a peer median of -9.7%.
- Net change in cash amounts to 13.4% of revenue for CRON, versus a peer median of 15.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $641.62M | +3223.9% | — | 91.4% | |
| LTM Mar 2026 | $172.46M | +253.2% | — | 21.7% | |
| LTM Mar 2026 | $139.3M | -239.9% | -37.4% | 19.0% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $57.3M | +6607.5% | — | — |
| LTM Mar 2026 | $31.41M | -71.4% | +81.7% | 15.3% | |
| LTM Mar 2026 | $27.5M | +148.0% | -17.8% | 13.4% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $20.45M | +222.7% | — | 102.3% |
| LTM Mar 2026 | $18.9M | -79.9% | — | 1.8% | |
| LTM Mar 2026 | $11.84M | -35.5% | -14.5% | 1.6% | |
| LTM Mar 2026 | $6.04M | +16.1% | -35.7% | 7.0% | |
| LTM Jun 2026 | $126K | -99.1% | — | 0.1% | |
| Peer median (excluding CRON) | $3.08M | -9.7% | -25.1% | 15.3% | |
Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (397.2M) | (168.73M) | (74.55M) | 40.02M | (2.93M) |
| Depreciation & Amortization | 15.4M | 13.12M | 8.11M | 9.34M | 14.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.15M | 15.12M | 8.77M | 8.7M | 7.05M |
| Change in Working Capital | (4.84M) | 15.66M | (26.47M) | (311K) | (35.02M) |
| Accounts Receivables | (12.16M) | (8.55M) | (6.59M) | (917K) | (26.2M) |
| Inventory | 11.57M | (7.22M) | 7.4M | 5.28M | (10.58M) |
| Accounts Payables | (1.6M) | (863K) | (773K) | (7.45M) | 1.13M |
| Other Working Capital | (2.65M) | 32.29M | (26.51M) | 2.77M | 636.96K |
| Other Non-Cash Items | 222.88M | 35.89M | 41.31M | (38.9M) | 42.73M |
| Operating Cash Flow | (153.62M) | (88.95M) | (42.84M) | 18.84M | 26.32M |
| Capital Expenditures | (12.26M) | (5.03M) | (3.42M) | (13.15M) | (26.17M) |
| Acquisitions (Net) | 0 | 0 | 0 | 5.71M | 2.9M |
| Purchases of Investments | (230M) | (271.38M) | (608.25M) | (8.34M) | (59.44M) |
| Sales of Investments | 215.3M | 268.87M | 532.84M | 181.9M | 5.15M |
| Other Investing Activities | (3.06M) | 4.12M | 18.42M | 8.41M | 0 |
| Investing Cash Flow | (28.9M) | (1.84M) | (59.5M) | 175.15M | (77.9M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (9.91M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (13.44M) | (2.9M) | (1.03M) | (1.23M) | (10.34M) |
| Financing Cash Flow | (13.44M) | (2.9M) | (1.03M) | (1.23M) | (20.25M) |
| Effect of Forex Changes | 4.91M | (28.64M) | 8.01M | (3.25M) | 3.89M |
| Net Change in Cash | (191.05M) | (122.33M) | (95.35M) | 189.51M | (67.94M) |
| Free Cash Flow | (165.88M) | (93.98M) | (46.26M) | 5.69M | 151.61K |
Cronos Group Inc.
NASDAQ:CRON
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.